Topic: Placebo Study

Greg Carlwood reviews the data from 203 historical contagion experiments cited in Daniel Roydas's book. He notes that in studies where healthy people were exposed to sick donors through coughing, sneezing, and shared items, only 12% became ill. Furthermore, 10% of control groups developed symptoms after receiving an inert placebo, suggesting that the nocebo effect and psychological expectation play a significant role in respiratory illness.

Del Bigtree discusses the Informed Consent Action Network (ICAN) and its focus on the lack of inert placebo testing in vaccine trials. He warns that rushed 12-18 month trials cannot account for autoimmune diseases that may take years to manifest.

A critical lack of inert placebo-controlled, double-blind safety studies for the 16 childhood vaccines is highlighted. Del Bigtree explains that manufacturers often use other vaccines or toxic adjuvants like aluminum as "controls" rather than saline, which masks the true side effect profile of the product. Health agencies justify the lack of true placebo groups by claiming it would be unethical to deny children a "life-saving" product, even before that product's safety has been scientifically established.

To meet the gold standard of medical research, Sententia has developed a double-blind protocol for energy healing. In this setup, the practitioner does not know if they are performing a real or placebo treatment until they are in a separate room from the patient. This removes the influence of practitioner confidence and unconscious cues, addressing the primary criticism of existing single-blind studies in the field.

The interview explores how drug and food companies manipulate data to gain FDA approval, such as submitting only the successful studies while ignoring failed trials. Consumers are urged to be their own "case agents" by checking labels for GMO derivatives like canola oil, soy oil, and high fructose corn syrup. The lack of long-term safety testing for these common ingredients is presented as a major public health oversight.